Shea E. Hogan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shea E. Hogan has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Marc P. Bonaca
CPC Clinical Research, Cardiovascular Division, University of Colorado School of Medicine, Aurora, Colorado, USA
4 shared publications - Scott D. Berkowitz
CPC Clinical Research, Aurora, CO, USA
4 shared publications - Judith Hsia
CPC Clinical Research, Aurora, CO, USA
3 shared publications Mark R Nehler
University of Colorado School of Medicine, Aurora, CO, USA
3 shared publications- Sonia Savitri Anand
Population Health Research Institute, McMaster University, Hamilton, ON, Canada
3 shared publications - Eva Muehlhofer
Bayer AG Research and Development, Pharmaceuticals, Wuppertal, Germany (E.M.).
2 shared publications
Latest Publications
- 23 June 2026
- Published by SAGE Publications in Vascular Medicine
- Vol. 31 (4) , 614-616
Vascular Disease Patient Information Page: Renal denervation
- 23 June 2026
- Published by SAGE Publications in Vascular Medicine
- Vol. 31 (4) , 614-616
Vascular Disease Patient Information Page: Renal denervation
- Open Access
- 22 June 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (8) , 105492
Parity in Patency? Efficacy of Resorbable Scaffold by Sex in LIFE-BTK
- 22 June 2026
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 5 (8) , 105492
Open AccessParity in Patency? Efficacy of Resorbable Scaffold by Sex in LIFE-BTK
- Open Access
- 4 November 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (21) , e039752
Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD
Background: VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities) demonstrated that antiplatelet therapy with rivaroxaban 2.5 mg twice daily compared with placebo reduced the first event in a composite end point in patients with peripheral artery disease after revascularization. The purpose of this analysis was to (1) evaluate whether rivaroxaban decreased the most severe events and (2) compare the harm and benefit of rivaroxaban on the same scale. Methods: Two exploratory, hierarchical analyses of the primary efficacy composite outcome and one exploratory analysis of the net clinical benefit composite outcome were prespecified. The global rank method and the win ratio method ranked components of the composite outcome by clinical importance. The net clinical benefit included both efficacy and safety outcomes. Results: The global rank method demonstrated that participants on rivaroxaban had fewer or later events than their placebo counterparts when events were compared in a hierarchical manner (primary ranking, P =0.0158). The win ratio approach demonstrated fewer or later fatal and nonfatal ischemic events in the rivaroxaban arm (win ratio, 1.16 [95% CI, 1.03–1.30]; P =0.0167). The net clinical benefit analysis revealed an overall beneficial effect of rivaroxaban when different efficacy and safety end points were included ( P <0.001). Conclusions: Evaluation of the VOYAGER PAD primary outcome exploring ranking of components revealed that (1) rivaroxaban decreased the most severe ischemic events and (2) that across different efficacy and safety outcomes, results consistently supported a favorable benefit–risk profile. These results help inform shared decision making on the use of rivaroxaban 2.5 mg twice daily with daily antiplatelet therapy. Registration: URL: https://www.clinicaltrials.gov ; unique identifier: NCT02504216.
- 4 November 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (21) , e039752
Open AccessRivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD
Background: VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities) demonstrated that antiplatelet therapy with rivaroxaban 2.5 mg twice daily compared with placebo reduced the first event in a composite end point in patients with peripheral artery disease after revascularization. The purpose of this analysis was to (1) evaluate whether rivaroxaban decreased the most severe events and (2) compare the harm and benefit of rivaroxaban on the same scale. Methods: Two exploratory, hierarchical analyses of the primary efficacy composite outcome and one exploratory analysis of the net clinical benefit composite outcome were prespecified. The global rank method and the win ratio method ranked components of the composite outcome by clinical importance. The net clinical benefit included both efficacy and safety outcomes. Results: The global rank method demonstrated that participants on rivaroxaban had fewer or later events than their placebo counterparts when events were compared in a hierarchical manner (primary ranking, P =0.0158). The win ratio approach demonstrated fewer or later fatal and nonfatal ischemic events in the rivaroxaban arm (win ratio, 1.16 [95% CI, 1.03–1.30]; P =0.0167). The net clinical benefit analysis revealed an overall beneficial effect of rivaroxaban when different efficacy and safety end points were included ( P <0.001). Conclusions: Evaluation of the VOYAGER PAD primary outcome exploring ranking of components revealed that (1) rivaroxaban decreased the most severe ischemic events and (2) that across different efficacy and safety outcomes, results consistently supported a favorable benefit–risk profile. These results help inform shared decision making on the use of rivaroxaban 2.5 mg twice daily with daily antiplatelet therapy. Registration: URL: https://www.clinicaltrials.gov ; unique identifier: NCT02504216.
- Open Access
- 19 August 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 4 (9)
Radial Artery Avulsion During Peripheral Intervention Managed With a Nonsurgical Approach: Case Report
- 19 August 2025
- Published by Elsevier in Journal of the Society for Cardiovascular Angiography & Interventions
- Vol. 4 (9)
Open AccessRadial Artery Avulsion During Peripheral Intervention Managed With a Nonsurgical Approach: Case Report
- 16 June 2025
- Published by SAGE Publications in Vascular Medicine
- Vol. 30 (3) , 324-325
Exercise therapy for symptomatic peripheral artery disease following lower-extremity revascularization in two large healthcare systems
- 16 June 2025
- Published by SAGE Publications in Vascular Medicine
- Vol. 30 (3) , 324-325
Exercise therapy for symptomatic peripheral artery disease following lower-extremity revascularization in two large healthcare systems
- Open Access
- 12 May 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (6) , 101763
Preserving Trial Endpoint Specificity and Cause of Death Attribution in Cardiovascular Trials
- 12 May 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (6) , 101763
Open AccessPreserving Trial Endpoint Specificity and Cause of Death Attribution in Cardiovascular Trials
- 30 April 2025
- Published by SAGE Publications in Vascular Medicine
- Vol. 30 (3) , 318-320
Prescription of aspirin plus low-dose rivaroxaban in patients with peripheral artery disease after lower-extremity revascularization
- 30 April 2025
- Published by SAGE Publications in Vascular Medicine
- Vol. 30 (3) , 318-320
Prescription of aspirin plus low-dose rivaroxaban in patients with peripheral artery disease after lower-extremity revascularization
- 30 October 2024
- Published by SAGE Publications in Vascular Medicine
- Vol. 29 (6) , 684-686
Defining patient goals for therapy in peripheral artery disease: A need for collaborative science
- 30 October 2024
- Published by SAGE Publications in Vascular Medicine
- Vol. 29 (6) , 684-686
Defining patient goals for therapy in peripheral artery disease: A need for collaborative science
- 23 August 2024
- Published by SAGE Publications in Vascular Medicine
- Vol. 29 (5) , 612-615
Executive Summary of Standard Operating Procedures for Society for Vascular Medicine (SVM) publications
- 23 August 2024
- Published by SAGE Publications in Vascular Medicine
- Vol. 29 (5) , 612-615
Executive Summary of Standard Operating Procedures for Society for Vascular Medicine (SVM) publications
- 20 February 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (8) , 635-637
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD
- 20 February 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (8) , 635-637
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD